ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2614 • 2012 ACR/ARHP Annual Meeting

    The Risk of Diabetes in Psoriatic Arthritis and Rheumatoid Arthritis

    Maureen Dubreuil1, Young Hee Rho2, Ada Man1, Yanyan Zhu3, Yuqing Zhang2, Thorvardur Love4, Alexis Ogdie5, Joel Gelfand6 and Hyon Choi7, 1Rheumatology, Boston University School of Medicine, Boston, MA, 2Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, 3Department of Biostatistics, Boston University School of Public Health, Department of Biostatistics, Boston University School of Public Health, Boston, MA, 4Landspitali University Hospital, Reykjavik, Iceland, 5Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA, 6University of Pennsylvania., Philadelphia, PA, 7Division of Rheumatology, Allergy, and Immunology Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: The potential impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on the risk of incident diabetes remains unclear.  Studies have shown that patients…
  • Abstract Number: 2615 • 2012 ACR/ARHP Annual Meeting

    Circulating Levels of Citrullinated Vimentin Fragments Are Diagnostic and Prognostic in Ankylosing Spondylitis; Evidence for Disease-Related Citrullination

    Anne C. Bay-Jensen1, Morten Asser Karsdal2, Efstathios Vassiliadis3, Stephanie Wichuk4, Zheng Zhao5, Robert GW Lambert6, Rik Lories7, Claus Christiansen8 and Walter P. Maksymowych9, 1Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience A/S, Herlev, Denmark, 3Nordic Bioscience, Herlev, Denmark, 4Medicine, University of Alberta, Edmonton, AB, Canada, 5Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, 6Radiology, University of Alberta, Edmonton, AB, Canada, 7Laboratory of Tissue Homeostasis and Disease - SBE Research Center, KU Leuven, Leuven, Belgium, 8CCBR, Ballerup, Denmark, 9Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: Rheumatoid arthritis (RA) is considered an anti-CCP positive disease whereas ankylosing spondylitis (AS) is considered an anti-CCP negative disease. Anti-CCP has prognostic capacity in…
  • Abstract Number: 2616 • 2012 ACR/ARHP Annual Meeting

    The Transition From Psoriasis (Ps) to Psoriatic Arthritis (PsA) Is Associated with Elevated Circulating Osteoclast Precursors (OCP) and Increased Expression of DC-STAMP

    Ya-Hui Chiu1, Edward M. Schwarz2, Dafna D. Gladman3, Sharon Moorehead4, Michelle Smith4, Rick Barrett4 and Christopher T. Ritchlin4, 1Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, 2Center for Musculoskeletal Research, University of Rochester, Rochester, NY, 3Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY

    Background/Purpose: Approximately 20% of psoriasis (Ps) patients (pts) develop psoriatic arthritis (PsA). Early diagnosis and therapy of PsA can limit bone and joint damage; however,…
  • Abstract Number: 2617 • 2012 ACR/ARHP Annual Meeting

    Outcomes Associated with Belimumab in Black/African American Patients with Systemic Lupus Erythematous in Clinical Practice Settings in the United States

    Christopher E. Collins1, Siva Narayanan2, Maria Dall'era3, Greg Dennis4, Alan Oglesby5, Mark B. McGuire6, Ramesh Pappu7, Charles T. Molta8 and Greg Keenan4, 1Rheumatology, Washington Hospital Ctr, Washington, DC, 2Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 4Human Genome Sciences, Inc., Rockville, MD, 5GlaxoSmithKline, Research Triangle Park, NC, 6Medical Data Analytics, Parsippany, NJ, 7GlaxoSmithKline, USA, Philadelphia, PA, 8GlaxoSmithKline, Philadelphia, PA

    Background/Purpose: Effectiveness of belimumab in black/African American (AA) patients (pts) with Systemic Lupus Erythematous (SLE) is yet to be adequately demonstrated. The objective of this…
  • Abstract Number: 2618 • 2012 ACR/ARHP Annual Meeting

    Lupus Disease Activity Severely Impairs Pandemic Influenza A/H1N1 Vaccine Immune Response in Patients without Therapy

    Eduardo F. Borba1, Sandra G. Pasoto1, Ana L. Calich1, Ricardo Fuller1, Vilma S.T. Viana1, Margareth Vendramini1, Joao Miraglia2, Maria A. Ishida3 and Eloisa Bonfa4, 1Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 2Instituto Butantan, Fundação Butantan, São Paulo, Brazil, 3Instituto Adolfo Lutz, São Paulo, Brazil, 4Rheumatology Division, University of São Paulo, Sao Paulo, Brazil

    Background/Purpose: To determine the influence of disease activity without the effect of drugs in pandemic 2009 influenza A (H1N1) vaccine immune response in untreated systemic…
  • Abstract Number: 2619 • 2012 ACR/ARHP Annual Meeting

    A Double-Blind Randomized Placebo-Controlled Trial of the Effect of Vitamin D3 On the Interferon Signature in Patients with Systemic Lupus Erythematosus

    Cynthia Aranow1, Maria Dall'era2, Elena M. Massarotti3, Meggan C. Mackay4, Andreea Coca5, Fotios Koumpouras6, Marc C. Levesque7, W. Winn Chatham8, Megan E. B. Clowse9, Lisa G. Criscione-Schreiber10, Sherri Callahan11, Ellen A. Goldmuntz12, Lynette Keyes-Elstein13, Betty Diamond14 and Diane L. Kamen15, 1Feinstein Institute for Medical Research, Manhasset, NY, 2Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 3Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 4Autoimmune & Musculoskeletal Disease, The Feinstein Institute, Manhasset, NY, 5Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, 6Lupus Center of Excellence, West Penn Hospital, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8University of Alabama at Birmingham, Birmingham, AL, 9Rheumatology, Duke University Medical Center, Durham, NC, 10Rheumatology, Duke University Health System, Durham, NC, 11Dait, NIAID/NIH Rm 6807, Bethesda, MD, 12DAIT, NIAID/NIH, Bethesda, MD, 13Rho Federal Systems, Inc., Chapel Hill, NC, 14Autoimmune & Musculoskeletal, Feinstein Institute Med Rsch, Manhasset, NY, 15Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC

    Background/Purpose: Exposure of normal PBMCs to1,25 OH vitamin D reverses the stimulatory effects of activating SLE sera on the interferon signature.  Given that IFN is…
  • Abstract Number: 2620 • 2012 ACR/ARHP Annual Meeting

    Randomized, Double-Blind, Placebo-Controlled Studies of P140 Peptide in Mannitol (Lupuzor) and Trehalose (Forigerimod) in Patients with SLE

    Robert Zimmer1, Daniel J. Wallace2 and Sylviane Muller3, 1ImmuPharma France, Mulhouse, France, 2Cedars-Sinai Medical Center, Los Angeles, CA, 3Institut de Biologie Moléculaire et Cellulaire, CNRS, Strasbourg, France

    Background/Purpose: Advances in the understanding of autoimmune diseases pathogenesis have led to the development of peptide-based therapies that aim to potentially reinstate tolerance to self…
  • Abstract Number: 2621 • 2012 ACR/ARHP Annual Meeting

    Sustained Disease Improvement and Safety Profile Over 1745 Patient-Year Experience (7 years) with Belimumab in Systemic Lupus Erythematosus Patients

    Joan T. Merrill1, Richard A. Furie2, Daniel J. Wallace3, William Stohl4, W. Winn Chatham5, Arthur Weinstein6, James D. McKay, Ellen M. Ginzler8, Z. John Zhong9, William W. Freimuth9 and Michelle Petri10, 1Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2North Shore-LIJ Health System, Lake Success, NY, 3Cedars-Sinai Medical Center, Los Angeles, CA, 4Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, 5University of Alabama at Birmingham, Birmingham, AL, 6Washington Hospital Center, Washington, DC, 7Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY, 8Human Genome Sciences, Inc., Rockville, MD, 9Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: To update belimumab safety and efficacy data over 7 y in patients with active SLE.  Methods: 449 SLE patients with SELENA-SLEDAI scores ≥4 were enrolled…
  • Abstract Number: 2622 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use:  Results of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

    K. Kalunian1, Joan T. Merrill2, R. Maciuca3, Wenjun Ouyang3, J. M. McBride3, Michael J. Townsend3, E. Park3, J. Li3, X. Wei3, A. Morimoto3, R. Boismenu3, John C. Davis Jr.3 and William P. Kennedy3, 1UCSD School of Medicine, La Jolla, CA, 2Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Genentech, Inc, South San Francisco, CA

    Background/Purpose: Dysregulation of interferon alpha (IFN) activity and/or signaling is implicated in systemic lupus (SLE).    This randomized, double-blind, placebo-controlled, two part Phase 2 study (ROSE)…
  • Abstract Number: 2623 • 2012 ACR/ARHP Annual Meeting

    Taking Charge of Systemic Sclerosis: A Pilot Study of an Internet Self-Management Program

    Janet L. Poole1, Dinesh Khanna2, Betty Skipper3 and Cindy F. Mendelson4, 1Occupational Therapy Program, University of New Mexico, Albuquerque, NM, 2Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 3Family and Community Medicine, University of New Mexico, NM, 4College of Nursing, University of New Mexico, Albuquerque, NM

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune connective tissue disease with serious implications for quality of life.  The disease is challenging due to the variable…
  • Abstract Number: 2624 • 2012 ACR/ARHP Annual Meeting

    Changes in Leisure Participation in Persons with Systemic Sclerosis

    Cindy F. Mendelson1, Jessica Greaves2 and Janet L. Poole3, 1College of Nursing, University of New Mexico, Albuquerque, NM, 2Occupational Therapy, University of New Mexico, Albuquerque, NM, 3Occupational Therapy Program, University of New Mexico, Albuquerque, NM

    Background/Purpose: Little attention has been devoted to understanding the difficulties and limitations people with systemic sclerosis (SSc) experience with leisure participation.  A qualitative interview study…
  • Abstract Number: 2625 • 2012 ACR/ARHP Annual Meeting

    The Impact of Sexual Difficulties in Women with Scleroderma and Interpersonal Relationships

    Tanaka Ngcozana1, Louise Parker1, Christopher P. Denton2 and Voon Ong3, 1Centre for Rheumatology and Connective Diseases, UCL Medical School and Royal Free Hosp, London, United Kingdom, 2Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, 3Department of Rheumatology, UCL Medical School, London, England

    Background/Purpose: Sexual problems are common in women with systemic sclerosis (SSc). SSc is a complicated condition linked to a number of complications including sexual dysfunction.…
  • Abstract Number: 2586 • 2012 ACR/ARHP Annual Meeting

    Tendon and Ligament Involvement in Gout: A Dual Energy Computed Tomography Study

    Nicola Dalbeth1, Ramanamma Kalluru2, Opetaia Aati3, Fiona M. McQueen4 and Anthony Doyle5, 1Medicine, University of Auckland, Auckland, New Zealand, 2Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, 3Department of Medicine, University of Auckland, Auckland, New Zealand, 4Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, 5University of Auckland, Auckland, New Zealand

    Background/Purpose: The involvement of bone and joints is widely recognized in gout.  However, soft tissue involvement is less well defined. Dual energy computed tomography (DECT)…
  • Abstract Number: 2587 • 2012 ACR/ARHP Annual Meeting

    Practice Makes Perfect: Assessment of Proficiency of Rheumatology Fellows in Specific Joint Procedural Skills

    Tara J. Rizvi1, Min Xu1 and Nancy Searle2, 1Rheumatology, Baylor College of Medicine, Houston, TX, 2Department of Pediatrics and Medicine, Baylor College of Medicine, Houston, TX

    Background/Purpose: Rheumatology training programs require fellows to be proficient in joint procedural skills as a requirement for graduation. However, specific procedures required to attain proficiency…
  • Abstract Number: 2588 • 2012 ACR/ARHP Annual Meeting

    Standardized Patient Simulation Improves Internal Medicine Resident Musculoskeletal Examination Skills

    Floranne C. Ernste1, Uma Thanarajasingam1, Courtney Shourt2, Andrew Halvorsen3 and Furman S. McDonald3, 1Division of Rheumatology, Mayo Clinic, Rochester, MN, 2Internal Medicine, Mayo Clinic Rochester, Rochester, MN, 3Internal Medicine, Mayo Clinic, Rochester, MN

    Background/Purpose: Few studies have addressed use of simulation-based education (SBE) to teach musculoskeletal (MSK) medicine to Internal Medicine (IM) residents. Our purpose was to obtain…
  • « Previous Page
  • 1
  • …
  • 2428
  • 2429
  • 2430
  • 2431
  • 2432
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology